Vemedia Group sells its pharmaceutical raw materials division ABC-Chemicals

26th November 2013 – Vemedia Group, a leading European OTC producer and distributor, acquired last year by funds advised by IK Investment Partners, will continue to further focus on OTC self-care products.

Vemedia Group has therefore sold its pharmaceutical raw materials division ABC-Chemicals SA, based in Wauthier-Braine (Belgium) to Euphaco.

Euphaco has recently been created by Mario Debel (ex-Omega Pharma), Ludwig Geldof (ex-2Pharma) and Hanne Dewulf (ex-2Pharma) together with the financial support and commitment of Indufin and Damier (Yvan Vindevogel).

Euphaco stands for European Pharmaceutical Compounding, which clearly reflects its intention to play a larger role in the market of raw materials and ingredients used for pharmaceutical compounding in pharmacies, hospitals and others, as demonstrated by this first acquisition. Euphaco intends to develop a broad range of raw materials and various accessories & services for the European market and wants to become a “Total Solution Partner” for its clients.

More information:
Euphaco: Mario Debel: – GSM +32 479 65 67 43
Vemedia Group: Rob Drenth: – Tel +31 20 519 83 00
Indufin: Joris Rome: – GSM +32 495 50 17 07

Vemedia Group (, with home markets in Netherlands, Belgium, France, Spain, Portugal and Italy is a leading and innovative player in OTC (prescription-free) medicines. The group is active in various European countries and also exports its products beyond Europe.

Damier is an international investment vehicle that focuses on a specific number of sectors by actively dedicating funds to companies with activities in the consumer sector (more specifically the consumer health business).

Indufin is ( is an investment company owned by Luxempart (a listed investment company in Luxembourg) and De Eik (a private investment company in Belgium), focusing on non-quoted companies. Indufin invests in successful medium-sized companies with ambitious growth plans. Indufin develops a strong partnership with its portfolio companies, based on a shared vision of the future and a relationship of trust. The current portfolio comprises 8 investments.

Download as pdf